HMGCR and prostate cancer: In contrast, genetically proxied inhibition of HMG-CoA reductase (OR: 0.85; 95% CI 0.73–1.00; P = 0.05) or NPC1L1 (OR: 1.23; 95% CI 0.92–1.63; P = 0.16) was not significantly associated with prostate cancer.